177 related articles for article (PubMed ID: 33391537)
1. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice.
Khan F; Gurung S; Gunassekaran GR; Vadevoo SMP; Chi L; Permpoon U; Haque ME; Lee YK; Lee SW; Kim S; Lee B
Theranostics; 2021; 11(3):1326-1344. PubMed ID: 33391537
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
[TBL] [Abstract][Full Text] [Related]
3. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
4. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.
Tremmel M; Matzke A; Albrecht I; Laib AM; Olaku V; Ballmer-Hofer K; Christofori G; Héroult M; Augustin HG; Ponta H; Orian-Rousseau V
Blood; 2009 Dec; 114(25):5236-44. PubMed ID: 19773544
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.
Recio JA; Merlino G
Cancer Res; 2003 Apr; 63(7):1576-82. PubMed ID: 12670907
[TBL] [Abstract][Full Text] [Related]
8. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
9. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
Ayoub NM; Alkhalifa AE; Ibrahim DR; Alhusban A
Med Oncol; 2021 Jan; 38(1):8. PubMed ID: 33449292
[TBL] [Abstract][Full Text] [Related]
10. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
12. Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins.
Hasenauer S; Malinger D; Koschut D; Pace G; Matzke A; von Au A; Orian-Rousseau V
PLoS One; 2013; 8(4):e62357. PubMed ID: 23626807
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
14. CD44 is required for two consecutive steps in HGF/c-Met signaling.
Orian-Rousseau V; Chen L; Sleeman JP; Herrlich P; Ponta H
Genes Dev; 2002 Dec; 16(23):3074-86. PubMed ID: 12464636
[TBL] [Abstract][Full Text] [Related]
15. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
[TBL] [Abstract][Full Text] [Related]
16. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.
Ghatak S; Hascall VC; Markwald RR; Misra S
J Biol Chem; 2010 Jun; 285(26):19821-32. PubMed ID: 20200161
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
18. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
19. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6.
Volz Y; Koschut D; Matzke-Ogi A; Dietz MS; Karathanasis C; Richert L; Wagner MG; Mély Y; Heilemann M; Niemann HH; Orian-Rousseau V
Biosci Rep; 2015 Jun; 35(4):. PubMed ID: 26181364
[TBL] [Abstract][Full Text] [Related]
20. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.
Damm S; Koefinger P; Stefan M; Wels C; Mehes G; Richtig E; Kerl H; Otte M; Schaider H
J Invest Dermatol; 2010 Jul; 130(7):1893-903. PubMed ID: 20357818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
